# Benchling **Source:** https://geo.sig.ai/brands/benchling **Vertical:** AI Software **Subcategory:** Life Sciences Software **Tier:** Emerging **Website:** benchling.com **Last Updated:** 2026-04-14 ## Summary Benchling is a life sciences R&D cloud platform with ~$200M+ ARR. Series E startup valued at ~$6.1B. Trusted by Pfizer, Genentech, and 1,000+ biotech/pharma teams. HQ: San Francisco. ## Company Overview Benchling is a cloud-based research and development platform purpose-built for the life sciences industry, founded in 2012 by Sajith Wickramasekara and Ashu Singhal as a Y Combinator alumnus. The company offers an integrated suite of tools including electronic lab notebooks (ELN), laboratory information management systems (LIMS), molecular biology design tools, and data management platforms, all connected in a unified cloud environment. Benchling has raised over $500M in venture capital, including a $200M Series E in 2021 that valued the company at approximately $6.1B. The platform serves more than 1,000 biotechnology, pharmaceutical, and contract research organizations globally, with notable customers including Pfizer, Genentech, Regeneron, Sanofi, and hundreds of emerging biotech companies. Estimated ARR exceeds $200M, driven by expansion within enterprise accounts. Benchling's model is enterprise SaaS with per-seat and platform licensing. Benchling's core value proposition is replacing disconnected legacy systems (paper notebooks, Excel, homegrown databases) with a unified, collaborative, and auditable R&D data platform that accelerates drug discovery timelines. The platform integrates with laboratory instruments, CROs, and enterprise systems like Veeva and Salesforce. As AI-driven drug discovery accelerates, Benchling is positioning itself as the data foundation layer for AI-powered R&D by providing structured, searchable scientific data to train models. It competes with LabVantage Solutions, Dotmatics (Instem), IDBS, and LabArchives. ## Frequently Asked Questions ### What is Benchling's annual revenue? Benchling is a private company. Industry estimates place its annual recurring revenue (ARR) at $200M+ as of 2024–2025. The company raised $200M in a 2021 Series E at a $6.1B valuation. ### Is Benchling publicly traded? No. Benchling is a privately held, venture-backed company. Major investors include Benchmark, Sequoia Capital, Altimeter Capital, and Thrive Capital. ### What does Benchling do? Benchling is a cloud R&D platform for life sciences organizations. It replaces paper lab notebooks and legacy LIMS/ELN systems with an integrated platform for experiment tracking, data management, molecular biology design, and regulatory compliance. ### Who uses Benchling? Benchling is used by 1,000+ biotechnology and pharmaceutical companies, including Pfizer, Genentech, Regeneron, Sanofi, and hundreds of emerging biotechs. It is used by R&D scientists, lab managers, and bioinformaticians. ### Who are Benchling's main competitors? Benchling competes with LabVantage Solutions, Dotmatics (now part of Instem), IDBS (BIOVIA), LabArchives, and Veeva Vault for ELN/LIMS market share. ### Where is Benchling headquartered? Benchling is headquartered in San Francisco, California, with additional offices in New York, Boston, and Zurich to serve global biopharma customers. ### How does Benchling integrate with lab instruments and ERP systems? Benchling connects to sequencers, liquid handlers, plate readers, and other lab instruments through its Benchling Connect integration layer, enabling automated data capture directly from instruments into structured datasets without manual entry. On the enterprise software side, Benchling integrates with SAP, Veeva Vault, and other ERP/LIMS systems through its REST API and pre-built connectors, supporting bidirectional data flows between R&D execution and regulatory or manufacturing systems. ### What is Benchling's pricing model and who are its primary competitors? Benchling uses an enterprise SaaS subscription model priced per user per year, with pricing tiers that vary based on modules (ELN, LIMS, Molecular Biology, Registry) and organization size — typical enterprise contracts run $500K–$2M+ annually for large pharma or biotech customers. Primary competitors include LabArchives (ELN focus), IDBS (acquired by Danaher), Dotmatics (now part of Insightful Science), and in-house LIMS solutions from companies like LabVantage. Benchling differentiates through its unified cloud platform that replaces multiple point solutions. ## Tags ai-powered, healthtech, north-america, saas, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*